Calidi Biotherapeutics, a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, announced Series A investments from two South Korean firms to advance manufacturing in preparation for Calidi's pre-IND and IND filings.
Eli Lilly is set to invest more than $470m to build a new pharmaceutical manufacturing facility in North Carolina, US.
Charles River Laboratories International has wrapped up its $380m acquisition of HemaCare, a California-based human-derived cellular products provider for the cell therapy market.
STADA Group, a German generic drug manufacturer, has agreed to acquire the prescription and consumer health business of Ukrainian pharmaceutical producer Biopharma for an undisclosed price.
Swiss pharmaceutical company Novartis has opened a new manufacturing facility for cell and gene therapies at Stein in Switzerland.
Lupin has signed a definitive agreement to sell the entire stake in its Japanese subsidiary Kyowa Pharmaceutical to Unison, a Japanese private equity fund, for JPY57.36bn ($526m).
Japan-based Takeda Pharmaceutical has opened a new dengue vaccine manufacturing facility in Singen, Germany.
Samsung Biologics announced the signing of a long-term agreement with Ichnos Sciences for manufacturing drug substance for ISB 830, an anti-OX40 monoclonal antibody in development as a potential treatment for moderate-to-severe atopic dermatitis.
Knight Therapeutics plans to acquire Brazilian pharma company Biotoscana Investments (GBT) for a price of around BRL1.16bn ($281m), which includes the latter’s financial debt.
Sartorius Stedim Biotech has agreed to acquire some of the life science businesses of US conglomerate Danaher for around $750m.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.